Evolving Discussions About Influenza Resistance

Edina Avdic, PharmD, MBA, BCPS-AQ ID, discusses how medical professionals are beginning to recognize influenza resistance.

Edina Avdic, PharmD, MBA, BCPS-AQ ID, discusses how medical professionals are beginning to recognize influenza resistance. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada.

Edina Avdic, PharmD, MBA, BCPS-AQ ID: Yes, I think that we are starting to talk a little bit more about resistance in recent years. Although resistance to neuraminidase inhibitors, particularly oseltamivir, has been reported in the literature, that’s predominantly occurred in patients who are immunocompromised, who may be shedding the virus for a longer time, and who had received the treatment for 7 to 10 days. Although resistance has been reported to neuraminidase inhibitors, it’s still pretty low globally. However, we don’t routinely test for resistance in our inpatient setting, and in our hospital laboratories. That’s only done, usually, by CDC or states for surveillance purposes. So we think the resistance is low, but we don’t really have a great sense [of] to what extent there is resistance.